HCV infects 170 million persons worldwide and causes significant morbidity in developed and developing countries. Therapies for HCV infection have improved recently, but still fail in many persons and are unavailable for most infected individuals worldwide. Therefore understanding natural immunity to this infection and the development of prophylactic vaccines and immunotherapies remain urgent goals. To this end, it will be essential to better understand the earliest events during acute HCV infection, as this is the exclusive time at which spontaneous clearance of viremia has been observed to occur. Over the previous funding period our center has been successful in collaboratively gaining new insights into various aspects of acute HCV infection, based on strong clinical cohorts and synergistic research projects. We have established two large cohorts of subjects with acute HCV infection contributing samples from highly complementary patient profiles that have allowed multiple successful collaborative projects, within and beyond the Center. At the National Reference Center for Viral Hepatitis at the Oswaldo Cruz Institute in Rio de Janeiro/Brazil we identify cases of acute symptomatic HCV with a high natural clearance rate and with unique success rates in long-term follow up of subjects. In Massachusetts we are studying the problem of acute HCV infection in recently incarcerated intravenous drug users, an important underserved population with a high risk of HCV exposure. The success of both cohorts allows us to carefully tailor the appropriate study population to each scientific question we want to address. To study the mechanisms leading to viral eradication or persistence we have developed novel highly sensitive and specific immunologic assays that allow for an unprecedented comprehensive assessment of NK cells and HCV-specific T-cell immune responses. Our approaches allow us to move beyond purely descriptive studies in humans to gain mechanistic insights in the correlates of protection and mechanisms of viral escape. We have also initiated multiple collaborations beyond the core members of this Center to investigate additional mechanisms not covered here, e.g. the role of neutralizing antibodies. In summary, we will collect comprehensive clinical, immunological and virological data from a large group of individuals with acute HCV infection, representing different routes of transmission, different clinical presentations and different outcomes of infection. We are confident that the comprehensive description of the complex interactions between human immune system and the virus will result in a significantly improved understanding of the mechanisms involved in viral control and persistence and will facilitate future preventative and therapeutic interventions against HCV infection.

Public Health Relevance

This HCV Cooperative Research Center will identify large numbers of subjects will acute HCV infection and will study their immune responses against the virus. The findings will be critical for our understanding of why some people are able to eradicate HCV spontaneously while the majority of subjects become chronically infected. This knowledge has the potential of fostering the development of HCV vaccines and therapies.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI066345-07
Application #
8102951
Study Section
Special Emphasis Panel (ZAI1-BP-M (J1))
Program Officer
Koshy, Rajen
Project Start
2005-08-17
Project End
2015-07-31
Budget Start
2011-08-01
Budget End
2012-07-31
Support Year
7
Fiscal Year
2011
Total Cost
$811,256
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Torres-Cornejo, Almudena; Lauer, Georg M (2017) Hurdles to the Development of Effective HBV Immunotherapies and HCV Vaccines. Pathog Immun 2:102-125
Wolski, David; Foote, Peter K; Chen, Diana Y et al. (2017) Early Transcriptional Divergence Marks Virus-Specific Primary Human CD8+ T Cells in Chronic versus Acute Infection. Immunity 47:648-663.e8
Rodrigo, Chaturaka; Walker, Melanie R; Leung, Preston et al. (2017) Limited naturally occurring escape in broadly neutralizing antibody epitopes in hepatitis C glycoprotein E2 and constrained sequence usage in acute infection. Infect Genet Evol 49:88-96
Rodrigo, C; Eltahla, A A; Bull, R A et al. (2017) Phylogenetic analysis of full-length, early infection, hepatitis C virus genomes among people with intravenous drug use: the InC3 Study. J Viral Hepat 24:43-52
Vergara, C; Thio, C; Latanich, R et al. (2017) Genetic basis for variation in plasma IL-18 levels in persons with chronic hepatitis C virus and human immunodeficiency virus-1 infections. Genes Immun 18:82-87
Rodrigo, Chaturaka; Eltahla, Auda A; Bull, Rowena A et al. (2016) Historical Trends in the Hepatitis C Virus Epidemics in North America and Australia. J Infect Dis 214:1383-1389
Page, Kimberly; Mirzazadeh, Ali; Rice, Thomas M et al. (2016) Interferon Lambda 4 Genotype Is Associated With Jaundice and Elevated Aminotransferase Levels During Acute Hepatitis C Virus Infection: Findings From the InC3 Collaborative. Open Forum Infect Dis 3:ofw024
Gunn, Bronwyn; Schneider, Jeffrey; Shansab, Maryam et al. (2016) Enhanced binding of antibodies generated during chronic HIV infection to mucus component MUC16. Mucosal Immunol 9:1549-1558
Doyle, J S; Deterding, K; Grebely, J et al. (2015) Response to treatment following recently acquired hepatitis C virus infection in a multicentre collaborative cohort. J Viral Hepat 22:1020-32
Sacks-Davis, Rachel; Grebely, Jason; Dore, Gregory J et al. (2015) Hepatitis C Virus Reinfection and Spontaneous Clearance of Reinfection--the InC3 Study. J Infect Dis 212:1407-19

Showing the most recent 10 out of 55 publications